{"id":128776,"date":"2018-06-20T16:22:48","date_gmt":"2018-06-20T20:22:48","guid":{"rendered":"https:\/\/www.countingpips.com\/?p=128776"},"modified":"2018-06-20T16:22:48","modified_gmt":"2018-06-20T20:22:48","slug":"agreement-facilitates-progress-toward-medical-device-approvals","status":"publish","type":"post","link":"https:\/\/www.investmacro.com\/forex\/2018\/06\/agreement-facilitates-progress-toward-medical-device-approvals\/","title":{"rendered":"Agreement Facilitates Progress Toward Medical Device Approvals"},"content":{"rendered":"
June 20, 2018<\/div>
\r\n<\/div><\/div>

By The Life Science Report<\/b><\/p>\n

Source: Streetwise Reports<\/em> \u00a0\u00a006\/20\/2018<\/a><\/b><\/p>\n

This medical device company enters a partnership to provide quality and regulatory services.<\/p><\/blockquote>\n

In a June 12 press release, Nu-Med Plus Inc. (NUMD:OTC.MKTS)<\/a> announced<\/a> a strategic partnership with Millenium Biosciences to provide “company quality and regulatory service.”<\/p>\n

Nu-Med manufactures medical devices for delivery of inhaled nitric oxide in hospital and other settings. Inhaled nitric oxide “is presently used in neonate hypoxia therapy (inadequate oxygen level in newborns), COPD (chronic obstructive pulmonary disease) and other pulmonary problems and may have future applications for a variety of other diseases and medical complications that are currently being investigated,” the company stated in the release.<\/p>\n

Jeff Robins, president and CEO of Nu-Med Plus, praised Millennium and its leader, Mike D’Amico, in the release, stating, “For the past 30+ years, Mr. D’Amico has been a successful professional in the Quality and Regulatory field in the capacities of quality project management and regulatory affairs. We are excited to have retained Millennium Biosciences as we aggressively step forward pursuing ISO 13485 training and certification for our company along with approvals for our products.”<\/p>\n

\n

Read what other experts are saying about:<\/p>\n